Too much to reply when I do not have the time but I will touch a few points.
The facility is NWBO's with all the licensing. NWBO can say to Advent take a hike and AZN or someone else could run the facility. As far as Flaskworks it is NWBO's and royalties are our ours no matter who uses it. It is a big deal and based on its use will determine final manufacturing pricing. But to be honest with you I do not see them using another CDMO. They have capacity at Sawston for roughly 250K patients for any type of tissue. So for me, the CRL argument falls short.
Market Data 
Markets 
AI
